P2.01-100 Spectrum of EGFR Exon 20 Insertion Mutations and Co-Occurring Genetic Alterations in Patients with Non-Small-Cell Lung Cancer
C. Kim(Georgetown University), Hirva Mamdani(Wayne State University), Rebecca Feldman(Caris Life Sciences (United States)), Alexander I. Spira(Virginia Cancer Specialists), Misako Nagasaka(University of California, Irvine), Peizhi Ma(West Virginia University), Abdul Rafeh Naqash(Oklahoma City University), Deepa S. Subramaniam(Georgetown University)
Cited by 3
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2024|369